Observational studyMedicine2016
Hormone replacement therapy benefits meibomian gland dysfunction in perimenopausal women.
Observational study in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- The lack of correlation between symptoms and signs in patients with meibomian gland dysfunction: a secondary analysis of the multicenter, randomized controlled trial.BMC ophthalmology · 2022Trial
- Clinical results of Intraductal Meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive Meibomian gland dysfunction: a randomized controlled trial.BMC ophthalmology · 2019Trial
- Age-Related Differences in the Efficacy of Intense Pulsed Light Therapy for Meibomian Gland Dysfunction in Women.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Focus on sex hormone axis disorder: exploring the susceptibility mechanism of dry eye in perimenopausal women.Frontiers in medicine · 2026Review
- Sex Differences in the Lacrimal Gland: Implications for Dry Eye Disease.International journal of molecular sciences · 2025Review
- Sex-based differences in conjunctival goblet cell responses to pro-inflammatory and pro-resolving mediators.Scientific reports · 2022Article
- Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease.Mediators of inflammation · 2018Review
- Glaucoma therapy: preservative-free for all?Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Serum Vitamin A Levels May Affect the Severity of Ocular Graft-versus-Host Disease.Frontiers in medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meibomian gland dysfunction (MGD) is believed to be the leading cause of dry eye (DE) disease worldwide. The connection between aging and MGD has long been recognized. However, few studies have addressed the relationship between MGD and hormone replacement therapy (HRT) in perimenopausal women, and not have examined the prevalence of MGD in perimenopausal women. The purpose of this study was to address and evaluate the possible relationship between MGD and HRT in perimenopausal women.The results suggest that perimenopausal women have a high prevalence of DE related to perimenopausal symptoms. The study also shows that perimenopausal women who use HRT can gain benefits for DE as well as for perimenopausal symptoms. Physicians caring for women who are experiencing DE related to perimenopausal symptoms should consider HRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.